{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:43:31Z","timestamp":1790516611330,"version":"4.1.0"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T00:00:00Z","timestamp":1520899200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003032","name":"Association Nationale de la Recherche et de la Technologie","doi-asserted-by":"publisher","award":["ANR-11-LABX-0048"],"award-info":[{"award-number":["ANR-11-LABX-0048"]}],"id":[{"id":"10.13039\/501100003032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["EL2013-3"],"award-info":[{"award-number":["EL2013-3"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001961","name":"AXA Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001961","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"DOI":"10.3389\/fmicb.2018.00278","type":"journal-article","created":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T08:43:12Z","timestamp":1520930592000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["How to Control HTLV-1-Associated Diseases: Preventing de Novo Cellular Infection Using Antiviral Therapy"],"prefix":"10.3389","volume":"9","author":[{"given":"Amandine","family":"Pasquier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Alais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Isabel","family":"Thoulouze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Journo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Dutartre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Mahieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1182\/blood-2010-02-270751","article-title":"Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors.","volume":"116","author":"Afonso","year":"2010","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003982","article-title":"Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission.","volume":"10","author":"Agosto","year":"2014","journal-title":"PLoS Pathog."},{"key":"B3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-1-4939-6872-5_4","article-title":"Quantitative analysis of human T-lymphotropic virus type 1 (HTLV-1) infection using co-culture with Jurkat LTR-luciferase or Jurkat LTR-GFP reporter cells.","volume":"1582","author":"Alais","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"10580","DOI":"10.1128\/JVI.01799-15","article-title":"Viral source-independent high susceptibility of dendritic cells to human T-cell leukemia virus type 1 infection compared to that of T lymphocytes.","volume":"89","author":"Alais","year":"2015","journal-title":"J. Virol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/gt.2012.18","article-title":"A reporter system for replication-competent gammaretroviruses: the inGluc-MLV-DERSE assay.","volume":"20","author":"Aloia","year":"2013","journal-title":"Gene Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1128\/AAC.46.9.3080-3083.2002","article-title":"Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro.","volume":"46","author":"Balestrieri","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1128\/AAC.00470-07","article-title":"Effect of phosphonated carbocyclic 2\u2032-oxa-3\u2032-aza-nucleoside on human T-cell leukemia virus type 1 infection in vitro.","volume":"52","author":"Balestrieri","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.antiviral.2005.09.001","article-title":"Protective effect of the acyclic nucleoside phosphonate tenofovir toward human T-cell leukemia\/lymphotropic virus type 1 infection of human peripheral blood mononuclear cells in vitro.","volume":"68","author":"Balestrieri","year":"2005","journal-title":"Antiviral Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1128\/AAC.37.2.332","article-title":"Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine.","volume":"37","author":"Balzarini","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"B10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0026-895X(25)13752-8","article-title":"The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2\u2032,3\u2032-didehydro-2\u2032,3\u2032-dideoxyribonucleosides: a comparison with their parental 2\u2032,3\u2032-dideoxyribonucleosides.","volume":"32","author":"Balzarini","year":"1987","journal-title":"Mol. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.12","article-title":"HTLV-1-associated myelopathy\/tropical spastic paraparesis.","volume":"1","author":"Bangham","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.semcancer.2013.11.003","article-title":"HTLV-1 clonality in adult T-cell leukaemia and non-malignant HTLV-1 infection.","volume":"26","author":"Bangham","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.1016\/j.ejmech.2011.06.034","article-title":"Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.","volume":"46","author":"Barral","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","article-title":"Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes.","volume":"28","author":"Bazarbachi","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.cell.2016.06.039","article-title":"Multiple origins of virus persistence during natural control of HIV infection.","volume":"166","author":"Boritz","year":"2016","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1128\/JVI.80.10.4771-4780.2006","article-title":"DC-SIGN facilitates fusion of dendritic cells with human T-cell leukemia virus type 1-infected cells.","volume":"80","author":"Ceccaldi","year":"2006","journal-title":"J. Virol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1021\/jm049399i","article-title":"Synthesis of phosphonated carbocyclic 2\u2032-oxa-3\u2032-aza-nucleosides: novel inhibitors of reverse transcriptase.","volume":"48","author":"Chiacchio","year":"2005","journal-title":"J. Med. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1021\/jm070285r","article-title":"Phosphonated carbocyclic 2\u2032-oxa-3\u2032-azanucleosides as new antiretroviral agents.","volume":"50","author":"Chiacchio","year":"2007","journal-title":"J. Med. Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","article-title":"Current status and prospects of HIV treatment.","volume":"18","author":"Cihlar","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1182\/blood-2014-02-553602","article-title":"The role of HTLV-1 clonality, proviral structure, and genomic integration site in adult T-cell leukemia\/lymphoma.","volume":"123","author":"Cook","year":"2014","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1128\/AAC.41.5.1082","article-title":"1592U 89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.","volume":"41","author":"Daluge","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2006-01-0067","article-title":"Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence.","volume":"108","author":"Datta","year":"2006","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nrd1877","article-title":"Acyclic nucleoside phosphonates: a key class of antiviral drugs.","volume":"4","author":"De Clercq","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"B24","doi-asserted-by":"publisher","first-page":"8461","DOI":"10.1128\/JVI.75.18.8461-8468.2001","article-title":"Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors.","volume":"75","author":"Derse","year":"2001","journal-title":"J. Virol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.antiviral.2010.02.001","article-title":"Human and viral nucleoside\/nucleotide kinases involved in antiviral drug activation: structural and catalytic properties.","volume":"86","author":"Deville-Bonne","year":"2010","journal-title":"Antiviral Res."},{"key":"B26","first-page":"2849","article-title":"Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation.","volume":"96","author":"El-Sabban","year":"2000","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"8333","DOI":"10.1073\/pnas.83.21.8333","article-title":"Phosphorylation of 3\u2032-azido-3\u2032-deoxythymidine and selective interaction of the 5\u2019-triphosphate with human immunodeficiency virus reverse transcriptase.","volume":"83","author":"Furman","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0304-3835(80)90146-9","article-title":"Inhibition by 2\u2032,3\u2032-dideoxythymidine of retroviral infection of mouse and human cells.","volume":"8","author":"Furmanski","year":"1980","journal-title":"Cancer Lett."},{"key":"B29","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1086\/322785","article-title":"Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.","volume":"184","author":"Garcia-Lerma","year":"2001","journal-title":"J. Infect. Dis."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological aspects and world distribution of HTLV-1 infection.","volume":"3","author":"Gessain","year":"2012","journal-title":"Front. Microbiol."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003263","article-title":"Strongyloidiasis and infective dermatitis alter human T lymphotropic virus-1 clonality in vivo.","volume":"9","author":"Gillet","year":"2013","journal-title":"PLoS Pathog."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1182\/blood-2010-10-312926","article-title":"The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones.","volume":"117","author":"Gillet","year":"2011","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-1-4939-6872-5_10","article-title":"High-throughput mapping and clonal quantification of retroviral integration sites.","volume":"1582","author":"Gillet","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1089\/aid.1991.7.1031","article-title":"Tropical spastic paraparesis\/HTLV-1-associated myelopathy (TSP\/HAM): treatment with an anabolic steroid danazol.","volume":"7","author":"Harrington","year":"1991","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"B35","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1086\/376531","article-title":"Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors.","volume":"188","author":"Hill","year":"2003","journal-title":"J. Infect. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.2174\/1381612033453668","article-title":"Phosphonomethoxyalkyl analogs of nucleotides.","volume":"9","author":"Holy","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1126\/science.1080115","article-title":"Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton.","volume":"299","author":"Igakura","year":"2003","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2012.00322","article-title":"Adult T-cell leukemia: a review of epidemiological evidence.","volume":"3","author":"Iwanaga","year":"2012","journal-title":"Front. Microbiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1212\/WNL.46.4.1016","article-title":"Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial.","volume":"46","author":"Izumo","year":"1996","journal-title":"Neurology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"12088","DOI":"10.1128\/JVI.79.18.12088-12094.2005","article-title":"Human immunodeficiency virus type 1 virological synapse formation in T cells requires lipid raft integrity.","volume":"79","author":"Jolly","year":"2005","journal-title":"J. Virol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"9344","DOI":"10.1128\/JVI.01079-13","article-title":"Human T lymphotropic virus type 1 SU residue 195 plays a role in determining the preferential CD4+ T cell immortalization\/transformation tropism.","volume":"87","author":"Kannian","year":"2013","journal-title":"J. Virol."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2017.08.016","article-title":"Glucose metabolism and oxygen availability govern reactivation of the latent human retrovirus HTLV-1.","volume":"24","author":"Kulkarni","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1182\/blood-2007-04-085076","article-title":"Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy\/tropical spastic paraparesis patients.","volume":"110","author":"Lezin","year":"2007","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3390\/v3050469","article-title":"Susceptibility of primary HTLV-1 isolates from patients with HTLV-1-associated myelopathy to reverse transcriptase inhibitors.","volume":"3","author":"Macchi","year":"2011","journal-title":"Viruses"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1099\/0022-1317-78-5-1007","article-title":"AZT inhibits the transmission of human T cell leukaemia\/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro.","author":"Macchi","year":"1997","journal-title":"J. Gen. Virol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/10428190400019966","article-title":"In vivo and in vitro treatment of HTLV-1 and HTLV-2 infected cells with arsenic trioxide and interferon-alpha.","volume":"46","author":"Mahieux","year":"2005","journal-title":"Leuk. Lymphoma"},{"key":"B47","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.1254194","article-title":"HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells.","volume":"345","author":"Maldarelli","year":"2014","journal-title":"Science"},{"key":"B48","doi-asserted-by":"publisher","first-page":"9525","DOI":"10.1128\/JVI.74.20.9525-9531.2000","article-title":"In vivo analysis of human T-cell leukemia virus type 1 reverse transcription accuracy.","volume":"74","author":"Mansky","year":"2000","journal-title":"J. Virol."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001675","article-title":"Ciclosporin A proof of concept study in patients with active, progressive HTLV-1 associated myelopathy\/tropical spastic paraparesis.","volume":"6","author":"Martin","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000788","article-title":"Quantitative comparison of HTLV-1 and HIV-1 cell-to-cell infection with new replication dependent vectors.","volume":"6","author":"Mazurov","year":"2010","journal-title":"PLoS Pathog."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-015-0221-1","article-title":"HTLV-1 drives vigorous clonal expansion of infected CD8+ T cells in natural infection.","volume":"12","author":"Melamed","year":"2015","journal-title":"Retrovirology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1046\/j.1365-2893.2001.00299.x","article-title":"Therapeutic management of hepatitis B-related cirrhosis.","volume":"8","author":"Merle","year":"2001","journal-title":"J. Viral Hepat."},{"key":"B53","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1128\/JVI.02660-06","article-title":"Phenotypic and genotypic comparisons of human T-cell leukemia virus type 1 reverse transcriptases from infected T-cell lines and patient samples.","volume":"81","author":"Mitchell","year":"2007","journal-title":"J. Virol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/325773a0","article-title":"Strategies for antiviral therapy in AIDS.","volume":"325","author":"Mitsuya","year":"1987","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","first-page":"7096","DOI":"10.1073\/pnas.82.20.7096","article-title":"3\u2032-Azido-3\u2032-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III\/lymphadenopathy-associated virus in vitro.","volume":"82","author":"Mitsuya","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1126\/science.1699273","article-title":"Molecular targets for AIDS therapy.","volume":"249","author":"Mitsuya","year":"1990","journal-title":"Science"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001729","article-title":"Ascorbic acid has superior ex vivo antiproliferative, cell death-inducing and immunomodulatory effects over IFN-alpha in HTLV-1-associated myelopathy.","volume":"6","author":"Moens","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3109\/13550289609146899","article-title":"Therapeutic trials in 200 patients with HTLV-I-associated myelopathy\/ tropical spastic paraparesis.","volume":"2","author":"Nakagawa","year":"1996","journal-title":"J. Neurovirol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3390\/v3060750","article-title":"Controversies in targeted therapy of adult T cell leukemia\/lymphoma: ON target or OFF target effects?","volume":"3","author":"Nasr","year":"2011","journal-title":"Viruses"},{"key":"B60","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/ana.20429","article-title":"Interferon-beta1a therapy in human T-lymphotropic virus type I-associated neurologic disease.","volume":"57","author":"Oh","year":"2005","journal-title":"Ann. Neurol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"6306","DOI":"10.1182\/blood-2011-04-349910","article-title":"Safety of long-term treatment of HAM\/TSP patients with valproic acid.","volume":"118","author":"Olindo","year":"2011","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1001\/archneur.63.11.1560","article-title":"Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study.","volume":"63","author":"Olindo","year":"2006","journal-title":"Arch. Neurol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nm.2065","article-title":"Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses.","volume":"16","author":"Pais-Correia","year":"2010","journal-title":"Nat. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators.","volume":"338","author":"Palella","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1084\/jem.168.3.1111","article-title":"Inhibition of human immunodeficiency virus (HIV-1\/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes\/macrophages by azidothymidine and related 2\u2032,3\u2032-dideoxynucleosides.","volume":"168","author":"Perno","year":"1988","journal-title":"J. Exp. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.antiviral.2015.03.003","article-title":"Enzymatic synthesis of acyclic nucleoside thiophosphonate diphosphates: effect of the alpha-phosphorus configuration on HIV-1 RT activity.","volume":"117","author":"Priet","year":"2015","journal-title":"Antiviral Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jneuroim.2012.05.004","article-title":"The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran.","volume":"250","author":"Rafatpanah","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"5553","DOI":"10.4049\/jimmunol.0903226","article-title":"Depletion of dendritic cells enhances susceptibility to cell-free infection of human T cell leukemia virus type 1 in CD11c-diphtheria toxin receptor transgenic mice.","volume":"184","author":"Rahman","year":"2010","journal-title":"J. Immunol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus.","volume":"125","author":"Ray","year":"2016","journal-title":"Antiviral Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.ejmech.2013.02.039","article-title":"Ester prodrugs of acyclic nucleoside thiophosphonates compared to phosphonates: synthesis, antiviral activity and decomposition study.","volume":"63","author":"Roux","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"B71","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.1128\/JVI.00282-09","article-title":"Simultaneous cell-to-cell transmission of human immunodeficiency virus to multiple targets through polysynapses.","volume":"83","author":"Rudnicka","year":"2009","journal-title":"J. Virol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1086\/380101","article-title":"Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy\/tropical spastic paraparesis.","volume":"189","author":"Saito","year":"2004","journal-title":"J. Infect. Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"B74","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2174\/1568026043388484","article-title":"Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.","volume":"4","author":"Sharma","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"B75","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ncb1544","article-title":"Retroviruses can establish filopodial bridges for efficient cell-to-cell transmission.","volume":"9","author":"Sherer","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nature10347","article-title":"Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy.","volume":"477","author":"Sigal","year":"2011","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/ncb1682","article-title":"Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission.","volume":"10","author":"Sowinski","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"B78","first-page":"59","article-title":"CROI 2016: advances in antiretroviral therapy.","volume":"24","author":"Taylor","year":"2016","journal-title":"Top. Antivir. Med."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-3-63","article-title":"Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopathy: a randomised trial.","volume":"3","author":"Taylor","year":"2006","journal-title":"Retrovirology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1038\/sj.onc.1208979","article-title":"Natural history of adult T-cell leukemia\/lymphoma and approaches to therapy.","volume":"24","author":"Taylor","year":"2005","journal-title":"Oncogene"},{"key":"B81","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.tim.2011.03.002","article-title":"Can viruses form biofilms?","volume":"19","author":"Thoulouze","year":"2011","journal-title":"Trends Microbiol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.canlet.2016.12.022","article-title":"Whole body clonality analysis in an aggressive STLV-1 associated leukemia (ATLL) reveals an unexpected clonal complexity.","volume":"389","author":"Turpin","year":"2017","journal-title":"Cancer Lett."},{"key":"B83","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/cas.12617","article-title":"Recent advances in the treatment of adult T-cell leukemia-lymphomas.","volume":"106","author":"Utsunomiya","year":"2015","journal-title":"Cancer Sci."},{"key":"B84","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/sj.bmt.1702731","article-title":"Improved outcome of adult T cell leukemia\/lymphoma with allogeneic hematopoietic stem cell transplantation.","volume":"27","author":"Utsunomiya","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"B85","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1182\/blood-2010-05-284141","article-title":"Requirement of the human T-cell leukemia virus p12 and p30 products for infectivity of human dendritic cells and macaques but not rabbits.","volume":"116","author":"Valeri","year":"2010","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1182\/blood-2016-09-692574","article-title":"Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells.","volume":"129","author":"Watanabe","year":"2017","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1128\/JVI.69.5.2863-2868.1995","article-title":"Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy.","volume":"69","author":"Wattel","year":"1995","journal-title":"J. Virol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.antiviral.2016.10.015","article-title":"Reducing the global burden of HTLV-1 infection: an agenda for research and action.","volume":"137","author":"Willems","year":"2017","journal-title":"Antiviral Res."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-2-4","article-title":"Increased proviral load in HTLV-1-infected patients with rheumatoid arthritis or connective tissue disease.","volume":"2","author":"Yakova","year":"2005","journal-title":"Retrovirology"},{"key":"B90","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/0166-0934(96)02078-2","article-title":"Highly sensitive qualitative and quantitative detection of reverse transcriptase activity: optimization, validation, and comparative analysis with other detection systems.","volume":"61","author":"Yamamoto","year":"1996","journal-title":"J. Virol. Methods"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2012.00389","article-title":"Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy\/tropical spastic paraparesis.","volume":"3","author":"Yamano","year":"2012","journal-title":"Front. Microbiol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0140-6736(86)92808-4","article-title":"Administration of 3\u2032-azido-3\u2032-deoxythymidine, an inhibitor of HTLV-III\/LAV replication, to patients with AIDS or AIDS-related complex.","volume":"1","author":"Yarchoan","year":"1986","journal-title":"Lancet"},{"key":"B93","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0168-1702(01)00285-4","article-title":"Efficacy of 3\u2032-azido 3\u2032deoxythymidine (AZT) in preventing HTLV-1 transmission to human cord blood mononuclear cells.","volume":"78","author":"Zhang","year":"2001","journal-title":"Virus Res."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053138","article-title":"Cell-to-cell transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV.","volume":"8","author":"Zhong","year":"2013","journal-title":"PLoS One"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmicb.2018.00278\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T19:14:55Z","timestamp":1751483695000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmicb.2018.00278\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,13]]},"references-count":94,"alternative-id":["10.3389\/fmicb.2018.00278"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2018.00278","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,13]]},"article-number":"278"}}